| Excerpt | Reference |
|---|
| "Lethal pulmonary embolism is associated with hypoxemia and hypocapnia in the vast majority of cases." | ( Hale, EH; Shankar, PS, 1978) |
| "Intra-operative pulmonary embolism is a rare and severe complication which is difficult to diagnose." | ( Maeda, A; Matsuki, A; Oshima, S, 1990) |
| "Pulmonary thromboembolism is one of the most frequent causes of death in our days." | ( Dürschmied, H; Haenselt, V; Mönch, C; Riedel, E; Sedlarik, KM, 1986) |
| "When pulmonary embolism is being investigated, R, due to its slower lung clearance, would appear to be preferable to D for patients suspected of increased bronchoalveolar permeability, especially if the time between nebulization and recording is greater than 10 min." | ( Chatal, JF; Peltier, P, 1986) |
| "Pulmonary thromboembolism is a rarity in India." | ( Bhusnurmath, B; Datta, BN; Ramesh, K, 1986) |
| "Because death due to pulmonary embolism is relatively rare following general surgery, many question the need for prophylaxis." | ( Hirsh, J; Hull, RD; Sackett, DL; Stoddart, GL, 1982) |
| "The sensitivity for pulmonary embolism is high (up to 98%)." | ( Rösler, H, 1984) |
| "Acute pulmonary embolism is one of the most serious of the life-threatening illnesses, but it can be prevented or effectively treated." | ( Brown, ML; Osmundson, PJ; Rosenow, EC, 1981) |
| "The diagnosis of pulmonary thromboembolism is frequently based on ventilation-perfusion scintigraphy and ascending lower limb venography when pulmonary angiography is not available." | ( Antoñana, MA; Calonge, J; Fernandez-Canton, G; Lopez Vidaur, I; Muñoz, F; Uresandi, F, 1994) |
| "The presentation of pulmonary embolism is most often in the form of the pulmonary hemorrhage-pulmonary infarction syndrome." | ( Stein, PD, 1994) |
| "Massive pulmonary embolism is defined as an anatomic obstruction of 50% or more of the pulmonary artery." | ( Pulmano, C; Shih, WJ, 1996) |
| "If pulmonary embolism is associated with a recent proximal venous thrombosis it would seem logical to propose surgical thrombectomy or thrombolysis, at least in young patients." | ( Bonnet, JL, 1995) |
| "Recurrent pulmonary embolism is an indication for filter placement, and this patient will need a long period of follow-up." | ( Moriya, T; Otaki, M; Suzuki, Y; Tabeta, H, 1997) |
| "Because pulmonary embolism is often silent, simple clinical procedures are desirable to identify patients with a low to intermediate probability of pulmonary embolism." | ( Inaba, S; Inoue, H; Irita, K; Mishima, H; Sakaguchi, Y; Takahashi, S; Taniguchi, S, 1997) |
| "Most commonly, a pulmonary embolism is the cause of the acute increase in right atrial pressure leading to a reversal of intracardiac flow and passage of venous embolic material to the left heart." | ( d'Audiffret, A; Dryjski, M; Ricotta, JJ; Shenoy, SS, 1998) |
| "In conclusion, pulmonary embolism is associated with alterations in lung surfactant and inflammation in lung tissue, expressed by an increase in PAF and in neutrophils." | ( Kitsiouli, EI; Lekka, ME; Nakos, G, 1998) |
| "Inhibition of PA on pulmonary thromboembolism is involved in the decrease of platelet aggregation and MDA production." | ( Pang, JX; Shan, CW; Sun, LS; Wang, XY; Yang, SQ, 1996) |
| "Although pulmonary embolism is a rare complication of sclerotherapy, it is potentially one of the most serious." | ( Nozaki, M; Sasaki, K; Yamaki, T, 1999) |
| "Hydatid pulmonary embolism is an uncommon condition resulting from the rupture of a hydatid heart cyst or the opening of a visceral hydatid cyst (often in the liver) into the venous circulation." | ( Abid, A; Ben Miled, K; Chebbi, ML; Dakhlaoui, R; Drira, I; El Mokhtar, E; Ellafi, A; Fennira, H; Hadoussa, J; Hamzaoui, A; Hantous, S; Kammoun, M; Keskes, H; Mistiri, I; Rekhis, O, 2000) |
| "As the risk for pulmonary embolism is similar in both groups, we speculate that the severity of medical illness in patients with both UEDVT and LEDVT may contribute to the higher mortality." | ( Ascher, E; Gunduz, Y; Hingorani, A; Mazzariol, F; Ramsey, PJ; Ward, M; Yorkovich, W, 2001) |
| "Acute pulmonary thromboembolism is fatal if the diagnosis and treatments are delayed." | ( Kadokura, M; Kataoka, D; Kawada, T; Nonaka, M; Takaba, T; Yamamoto, S, 2002) |
| "Fatal pulmonary embolism is estimated to occur in nearly 1% of these women." | ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2003) |
| "The detection of pulmonary embolism is still challenging due to the often nonspecific clinical findings." | ( Botnar, RM; Buecker, A; Günther, RW; Katoh, M; Mahnken, AH; Parsons, EC; Spuentrup, E; Wiethoff, AJ, 2005) |
| "Pulmonary thromboembolism is rarely recognized in young children, even in hospital settings." | ( Chakraborty, S; Rao, NK; Sridhar, AV, 2005) |
| "Massive pulmonary embolism is a potentially treatable catastrophic event after cesarean delivery, even if continuous cardiopulmonary resuscitation is required until life-saving embolectomy is done." | ( Greyson, B; Hilton, FL; Marty, AT; Spear, RK, 2005) |
| "However, pulmonary embolism is rarely documented as a fatal adverse effect." | ( Chang, JY; Chen, LT; Chuang, TR; Lee, WS; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J, 2005) |
| "Pulmonary thromboembolism is the leading direct cause of maternal deaths in the UK." | ( Tan, EK; Wisdom, SJ, 2006) |
| "Although acute pulmonary embolism is epidemiologically associated with chronic thromboembolic pulmonary hypertension, the factors responsible for resistance to thrombolysis and a shift toward vascular remodeling within the pulmonary arteries of patients with chronic thromboembolic pulmonary hypertension are unknown." | ( Auger, WR; Chiles, PG; Fedullo, PF; Marsh, JJ; Morris, TA; Woods, VL, 2006) |
| "Severe glue pulmonary embolism is a rare complication of injection therapy." | ( Alexander, S; Korman, MG; Sievert, W, 2006) |
| "Prevention of pulmonary embolism is essential in high risk patients." | ( Pardina, B; Parramón, F; Pineda, O; Rodríguez, J; Ruiz, B; Villalonga, A, 2007) |
| "Massive pulmonary embolism is a life-threatening condition to be treated with anticoagulants or even thrombolytic agents in selected cases." | ( Gualeni, A; Oneglia, C, 2008) |
| "Fatal pulmonary embolism is estimated to occur in nearly 1% of these women." | ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2007) |
| "Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen." | ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "Acute pulmonary embolism is the third most common cause of cardiovascular mortality." | ( Mühl, D, 2008) |
| "Massive pulmonary embolism is defined by systemic hypotension or cardiogenic shock." | ( Marié, E; Meyer, G; Planquette, B; Sanchez, O; Wermert, D, 2008) |
| "Brain metastases and pulmonary embolism are life-threatening conditions because of the risk of fatal endocranic hypertension and severe dyspnea." | ( Antonelli, G; Colina, P; Ferraù, F; Giamo, V; Parisi, A; Rotondo, S; Sessa, E; Vitale, FV, 2011) |
| "Hydatid pulmonary embolism is an uncommon condition resulting from the rupture of a hydatid heart cyst or the opening of a visceral hydatid cyst into the venous circulation." | ( Akgun, V; Battal, B; Daku, A; Deniz, O; Karaman, B; Ors, F, 2011) |
| "Massive pulmonary embolism is a life threatening pathology with a high mortality over 20%." | ( Ba, SA; Bodian, M; Dia, MM; Diao, M; Diop, IB; Kane, A; Kane, AD; Mbaye, A; Mohamed, A; Ndiaye, MB; Sarr, M; Yameogo, NV, 2011) |
| "Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication." | ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013) |
| "Acute pulmonary embolism is a critical condition associated with increased mortality." | ( Kiss, T; Muhl, D; Neto-Neves, EM; Tanus-Santos, JE, 2013) |
| "Thus, pulmonary thromboembolism is an inevitable consequence of successful adulticide therapy." | ( Carretón, E; González-Miguel, J; Juste, MC; Montoya-Alonso, JA; Morchón, R; Simón, F, 2013) |
| "Pulmonary thromboembolism is a relatively rare entity in the pediatric population; however, it should always be part of the differential diagnosis in patients with the appropriate clinical presentation." | ( Chen, AE; Low, DW; Sing, AC; Webb, JL, 2013) |
| "Hydatid pulmonary embolism is extremely rare and is due to rupture of a cardiac hydatid cyst or, more rarely, rupture of a hepatic hydatid cyst." | ( Amara, B; Benjelloun, MC; El Biaze, M; El Houari, A; Kamaoui, I; Ouadnouni, Y; Sahnoune, F; Serraj, M; Smahi, M; Tizniti, S, 2013) |
| "The presence of pulmonary embolism is unusual and may be the consequence of prolonged immobilization." | ( Chen, SM; Ku, MS; Lin, CH; Sheu, JN; Tsai, JD; Tsao, TF, 2014) |
| "When pulmonary embolism is suspected, use a clinical decision rule (eg, the Wells rule, the Geneva rule) to establish the probability of this condition." | ( Delzell, JE, 2013) |
| "PE pulmonary embolism is more common than RVT renal vein thrombosis , is most often asymptomatic, and is most frequently found in patients with membranous nephropathy." | ( Li, SJ; Lu, GM; Meinel, FG; Nance, JW; Schoepf, UJ; Zhang, LJ; Zhang, Z; Zhao, YE; Zhou, CS, 2014) |
| "The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs)." | ( Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P, 2015) |
| ": Pulmonary embolism is a life-threatening disease which represents with high mortality and morbidity." | ( Demirci, G; Guler, A; Kalkan, AK; Uygur, B; Yildiz, M; Zencirkiran Agus, H, 2018) |
| "Pulmonary thromboembolism is a condition that is familiar to forensic pathologists for its common cause of sudden unexpected death." | ( Srettabunjong, S, 2019) |
| "Patients with acute pulmonary embolism are at intermediate-high risk in the presence of imaging signs of right ventricular dysfunction plus one or more elevated cardiac biomarker." | ( Antunes, RM; Bicho Augusto, J; Brito, J; Campos, L; Correia, D; Faria, D; Ferreira, J; Freitas, P; Gago, M; Gonçalves, M; Lynce, A; Mendes, M; Morais, C; Oliveira, A; Oliveira, J; Santos, A; Santos, AR; Simões, J, 2020) |
| Excerpt | Reference |
|---|
| "The incidence of pulmonary embolism was no greater with streptokinase than with heparin treatment." | ( Benz, A; Da Silva, MA; Duckert, F; Madar, G; Müller, G; Nyman, D; Prisender, S; Schmitt, HE; Widmer, LK, 1975) |
| "For the prevention of pulmonary embolism in patients with severe ischemia or gangrene of the lower extremities, it is recommended that operative treatment (corrective operations on the arteries or amputation) should be combined with inspection of the major veins." | ( Isaev, MR; Reviakin, VI; Zatevakhin, II, 1978) |
| "Objective documentation of pulmonary embolism is an essential prerequisite for appropriate treatment (Figure 7)." | ( Duranceau, A; Jones, RH; Sabiston, DC, 1976) |
| "The phase II Urokinase-Streptokinase Pulmonary Embolism Trial (USPET) was begun to assess the comparative results of UK and Streptokinase (SK) therapy." | ( Bell, WR; Sasahra, AA; Sherry, S; Simon, TL; Stengle, JM, 1975) |
| "Because of pulmonary embolism phenprocoumon had been administered for four months." | ( Bollinger, A; Imbach, P; Schneider, E; Steurer, J, 1992) |
| "In a rat model of acute unilateral pulmonary embolism (n = 5), perfusion defects were identified after administration of polylysine-(gadopentetate dimeglumine)40, but no ventilation abnormality was seen after inhalation of gadopentetate dimeglumine." | ( Berthezène, Y; Brasch, RC; Clément, O; Moseley, ME; Mühler, A; Vexler, V, 1992) |
| "The authors report a case of massive pulmonary embolism revealing thrombocytopenia induced by a low molecular weight heparin (LMWH) initially proposed for the treatment of superficial phlebitis." | ( Bajolet, A; Chapoutot, L; Elaerts, J; Graciet, J; Grentzinger, A; Metz, D; N'Guyen, P; Taupin, JM, 1991) |
| "In a hamster pulmonary embolism model, the rscu-PA/MA-FU1-74 complex had a 13- to 17-fold increased thrombolytic potency (percent lysis per mg/kg u-PA administered) relative to that of rscu-PA." | ( Collen, D; Iwasa, S; Kakinuma, A; Kurokawa, T; Lijnen, HR; Stassen, JM, 1991) |
| "Undiagnosed and untreated pulmonary embolism has a high mortality rate; thus, a high index of clinical suspicion and reliable diagnostic modalities are necessary to ensure prompt and accurate diagnosis." | ( Hackbarth, R; Kuhns, L; Sarnaik, A, 1991) |
| "Two cases of massive pulmonary embolism observed in patients under estrogen therapy, are presented." | ( Amaro Cendon, A; Antela Carrera, C; Antela López, A; Gil de la Peña, M; González-Juanatey, JR; Masa Vázquez, L; Requena Caballero, I, 1990) |
| "We report a patient with massive pulmonary embolism and circulatory shock during pregnancy (31st gestational week) and preterm labour who has been successfully treated with recombinant tissue type plasminogen activator." | ( Breulmann, M; Flossdorf, T; Hopf, HB, 1990) |
| "Asymptomatic pulmonary embolism was treated with oral anticoagulation only." | ( Jones, K; Lachiewicz, PF; McCardel, BR, 1990) |
| "Following pulmonary embolism there was no significant difference in haemodynamic variables between control and teprotide treated rats." | ( Hoferer, P; Riegger, GA, 1990) |
| "Only 1 patient suffered a recurrent pulmonary embolism, and this occurred during an episode of gastrointestinal bleeding, when anticoagulant therapy had to be discontinued prematurely." | ( Altschuler, E; Moosa, H; Selker, RG; Vertosick, FT, 1990) |
| "Non-fatal pulmonary embolism after onset of treatment occurred in both cohorts with an equal frequency of 13%." | ( Gänger, KH; Nachbur, BH; Ris, HB; Zurbrügg, H, 1989) |
| "A 65-year-old female patient with pulmonary embolism developed widespread, extremely painful hemorrhagic necroses of the skin and subcutaneous tissue of the lower extremities 5 weeks after initiation of anticoagulation therapy." | ( Diem, E; Rappersberger, K; Tanew, A, 1988) |
| "'Non-lethal' pulmonary embolism diagnosed by lung perfusion scintigraphy and by chest X-rays, developed in 2 patients treated with LDH and in one treated with HDHE." | ( Hetényi, L; Izinger, E; László, E; Magyary, F; Sándor, T; Turcsányi, G, 1986) |
| "Anticoagulation is warranted for pulmonary embolism, with fibrinolytic therapy reserved for patients with massive embolism and hemodynamic compromise." | ( Adams, PC; Kakkar, VV, 1986) |
| "Patients with massive unilateral pulmonary embolism can be efficiently treated with intra-arterial lytic therapy." | ( Comerota, AJ; Rubin, RN; Sherry, S; Soulen, RL; Tyson, RR; White, JV; Williams, FF, 1987) |
| "The incidence of pulmonary embolism was examined in a series of 83 patients who had received chemotherapy for advanced ovarian cancer and ten embolic episodes occurred." | ( Canney, PA; Wilkinson, PM, 1985) |
| "Twenty-nine patients with acute pulmonary embolism, each one diagnosed by means of perfusion lung scan and selective pulmonary arteriography, were admitted to the study and randomly allocated to three treatment groups: A, 10 patients, urokinase: 800,000 CTA units/day for three days followed by oral anticoagulants; B, 9 patients, heparin: mean daily dose 30,000 units for seven days followed by oral anticoagulants; C, 10 patients, urokinase: 3,300,000 CTA units in 12 hours followed by oral anticoagulants." | ( Di Ricco, G; Giacomelli, V; Giuntini, C; Marini, C; Palla, R; Rindi, M, 1984) |
| "Massive pulmonary embolism causes an acute pressure overload for the right ventricle associated with a drop in cardiac output leading, if untreated, to cardiogenic shock." | ( Bühlmann, AA, 1984) |
| "Acute pulmonary embolism is one of the most serious of the life-threatening illnesses, but it can be prevented or effectively treated." | ( Brown, ML; Osmundson, PJ; Rosenow, EC, 1981) |
| "Patients with pulmonary embolism or deep venous thrombosis were randomly assigned to receive either intermittent or continuous intravenous heparin therapy." | ( Bynum, LJ; Parkey, RW; Wilson, JE, 1981) |
| "For treatment of pulmonary thromboembolism, continuous conventional-dose heparin therapy is the approach of choice." | ( Giudice, JC; Kaufman, J; Komansky, HJ, 1980) |
| "In this group of patients, therefore, pulmonary embolism should be demonstrated by angiography before long-term anticoagulant therapy is prescribed." | ( Bustad, L; Cheely, R; Delany, DJ; Griggs, TR; McCartney, WH; Perry, JR; Wynia, VH, 1981) |
| "The objectives of treating patients with pulmonary embolism are to prevent death, to reduce morbidity from the acute event, and to prevent thromboembolic pulmonary hypertension." | ( Agnelli, G, 1995) |
| "The mortality rate of untreated pulmonary embolism approaches 30%, and the best way to prevent death is by swift diagnosis and initiation of therapy." | ( Evans, DA; Wilmott, RW, 1994) |
| "The severity of pulmonary thromboembolism and pulmonary hypertension induced by heartworms dying after administration of 2 adulticides was evaluated." | ( Duncan, JR; Lewis, RE; Rawlings, CA; Raynaud, JP, 1993) |
| "A case of shock and pulmonary embolism in a 57-year-old woman is described in which hemodynamics were unresponsive both to usual therapy (volume loading, dobutamine, thrombolysis) and then to norepinephrine." | ( Boulain, T; Lanotte, R; Legras, A; Perrotin, D, 1993) |
| "Patients with submassive pulmonary embolism should presently be treated with adjusted dose unfractionated heparin and coumarins." | ( Büller, HR; Koopman, MM; Prins, MH; ten Cate, JW, 1995) |
| "The incidence of pulmonary embolism before treatment was investigated using scintigraphy." | ( Graf, AH; Graf, B; Staudach, A; Traun, H, 1996) |
| "There was no pulmonary embolism recurrence nor major bleeding in either group during the treatment period." | ( Brenot, F; Charbonnier, B; Gillet Juvin, K; Meyer, G; Pacouret, G; Simonneau, G; Sors, H, 1995) |
| "The treatment of the pulmonary embolism depends on its size, its tolerance, the embolic source and sites of embolism." | ( Bonnet, JL, 1995) |
| "In a model of fatal pulmonary thromboembolism induced by intravenous injection of ADP (300 micrograms/g), YC-1 was effective in reducing mortality when administered intraperitoneally at doses of 10-30 micrograms/g." | ( Ko, FN; Kuo, SC; Lee, FY; Teng, CM; Wu, CC, 1997) |
| "We present a case of pulmonary embolism successfully treated with low molecular weight heparin in a woman with a major grade placenta praevia, who required emergency operative delivery." | ( Hertzberg, M; Lahoud, R; Nicholl, M; Rowlands, S, 1997) |
| "Despite anticoagulant therapy, pulmonary embolism recurred so we implanted a Greenfield filter in the inferior vena cava." | ( Moriya, T; Otaki, M; Suzuki, Y; Tabeta, H, 1997) |
| "The one pulmonary embolism was successfully treated with heparin." | ( Abnet, JK; Ista, C; Kos, PB; Wood, KB, 1997) |
| "We describe a case of pulmonary embolism and ischemic stroke due to paradoxical embolism in a healthy young woman taking oral contraceptives to treat an ovarian cyst." | ( Fronticelli, M; Mandorla, S; Taliani, MR, 1997) |
| "Patients with pulmonary embolism (PE) and echocardiographic signs of right ventricular overload have worse prognosis and may require aggressive therapy." | ( Chlebus, M; Gurba, H; Kuch-Wocial, A; Pacho, R; Pruszczyk, P; Pruszynski, B; Torbicki, A, 1997) |
| "In patients suspected to have pulmonary embolism who have nondiagnostic lung scan and adequate cardiorespiratory reserve, serial noninvasive leg testing is a practical approach that avoids pulmonary angiography, identifies patients who have proximal vein thrombosis requiring treatment, and avoids the risks of anticoagulant treatment in the majority of patients." | ( Raskob, GE, 1995) |
| "The thrombophlebitis and subsequent pulmonary embolism probably reflect the hypercoagulable state seen in sickle cell and are not due to the deferoxamine therapy." | ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997) |
| "We reported four cases of pulmonary embolism where the administration of inhaled NO resulted in an improvement in pulmonary haemodynamic and gas-exchange parameters." | ( Balvay, P; Barale, F; Belle, E; Blasco, G; Capellier, G; Jacques, T, 1997) |
| "The incidence of deep vein thrombosis or pulmonary embolism in more than 500 patients undergoing hip surgery was similar for these 3 treatments." | ( Goa, KL; McNeely, W, 1998) |
| "The paper deals with fatal pulmonary embolism in patients treated at STOCER after spinal injuries, frequently with neurological impairment." | ( Jagodziński, K; Kiwerski, JE; Krasuski, M; Krzyzosiak, L, 1998) |
| "We propose that the pulmonary thromboembolism observed in this case was related to the initial pulmonary involvement of Takayasu arteritis, since the patient's symptoms, ESR and CRP levels all improved markedly following the administration of prednisolone." | ( Kashiwabara, K; Kiguchi, T; Kishi, K; Kobayashi, K; Kusama, H; Matsuoka, T; Nakamura, H; Sarashina, G; Yagyu, H, 1998) |
| "The prevalence of pulmonary thromboembolism at autopsy was assessed in a retrospective study of a cohort of 185 patients undergoing maintenance hemodialysis treatment who died in the last decade." | ( Balcke, P; Bankl, H; Barbieri, G; Harm, F; Hauser, AC; Kitzwögerer, M; Pribasnig, A; Wiesholzer, M, 1999) |
| "A case of acute pulmonary embolism following high ligation and compression sclerotherapy for varicose veins is reported." | ( Nozaki, M; Sasaki, K; Yamaki, T, 1999) |
| "An accurate diagnosis of pulmonary embolism is essential to prevent excessive morbidity and mortality from either inappropriate therapy or failure to institute anticoagulation." | ( Cohn, JR; More O'Ferrall, DJ; Rider-Foster, D, 1999) |
| "The frequency of recurrent pulmonary embolism among patients with nonmassive acute pulmonary embolism and negative serial noninvasive leg tests who were not treated was estimated from two prospective studies of the noninvasive management of patients with suspected pulmonary embolism." | ( Hull, RD; Raskob, GE; Stein, PD, 2000) |
| "The frequency of nonfatal recurrent pulmonary embolism among untreated patients was 3%, regardless of whether they had negative serial impedance plethysmograms or negative serial compression ultrasonograms." | ( Hull, RD; Raskob, GE; Stein, PD, 2000) |
| "In acute massive pulmonary embolism with hemodynamic instability, monitoring of pulmonary artery pressure can be used to assess the efficacy of thrombolytic therapy." | ( Djonlagic, H; Giannitsis, E; Katus, HA; Kurowski, V; Wiegand, UK, 2000) |
| "In 12 patients with massive pulmonary embolism who required mechanical ventilation, mean pulmonary arterial pressure (MPAP) and end-tidal carbon dioxide tension (ETCO2) were registered continuously during thrombolytic therapy." | ( Djonlagic, H; Giannitsis, E; Katus, HA; Kurowski, V; Wiegand, UK, 2000) |
| "Patients with acute pulmonary embolism and venous thromboembolism are usually treated with anticoagulant therapy for at least 3 months as the optimum duration." | ( Kohno, M; Mizushige, K; Ohmori, K; Tanimoto, K; Ueda, T; Yoshihiro, W; Yukiiri, K, 2001) |
| "If patients with pulmonary embolism meet criteria demonstrated to result in a higher risk of death, it is, of course, reasonable to not treat such patients on an outpatient basis." | ( Wells, PS, 2001) |
| "In a canine autologous blood clot pulmonary embolism model, ET(A) receptor antagonist ZD2574 (10 mg/kg, intravenous; ZD2574 group; n = 6) or vehicle (control group; n = 5) was administered." | ( Chun, YG; Hong, SB; Kim, DS; Kim, WD; Kim, WS; Koh, Y; Lee, IC; Lee, JH; Lee, SD; Lim, CM; Shim, TS; Tuder, RM, 2001) |
| "Tinzaparin reduced health care costs for pulmonary embolism due to easier administration, less complex laboratory tests, and personnel time savings." | ( Achkar, A; Allenet, B; Elias, A; Khalifé, K; Lewis, D; Simonneau, G, 2001) |
| "127 patients with documented acute pulmonary embolism were treated with different regimens: thrombolysis combined with anticoagulant therapy in 70 cases, thrombolytic therapy alone in 31 cases and pure anticoagulant therapy in 26 cases." | ( Chen, G; Chen, Y; Cheng, L; Cheng, X; Gao, M; He, J; Li, S; Xiong, C; Zhang, Z; Zhao, J; Zhao, M; Zhou, S, 2002) |
| "Acute pulmonary thromboembolism is fatal if the diagnosis and treatments are delayed." | ( Kadokura, M; Kataoka, D; Kawada, T; Nonaka, M; Takaba, T; Yamamoto, S, 2002) |
| "We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a "bridge" to warfarin, target INR 2." | ( Beckman, JA; Dunn, K; Goldhaber, SZ; Sasahara, AA, 2003) |
| "Patients with pulmonary embolism have a substantial risk for recurrence after discontinuation of oral anticoagulation, regardless of treatment duration." | ( Ageno, W; Agnelli, G; Becattini, C; Imberti, D; Miccio, M; Poggio, R; Pogliani, E; Porro, F; Prandoni, P; Silingardi, M; Taliani, MR; Zonzin, P, 2003) |
| "The importance of pulmonary embolism (PE) due to venous thrombosis is recognized in the treatment of vascular diseases." | ( Kozawa, O; Matsuno, H; Matsuo, O; Okada, K; Ueshima, S, 2003) |
| "To establish a canine model of pulmonary thromboembolism (PTE) for evaluating the effects of thrombolytic therapy." | ( Li, C; Pang, BS; Wang, C; Wang, F; Wang, T; Weng, XZ; Wu, YB; Yang, YH; Zhang, HY, 2003) |
| "We report two cases of pulmonary embolism associated with sclerotherapy for peripheral vascular malformations." | ( Kaseno, S; Kemmotsu, O; Kobayashi, S; Kojima, T; Tachibana, K, 2004) |
| "To describe the occurrence of pulmonary embolism (PE) as a rare adverse effect of clozapine that is treatable, but sometimes fatal, and survey the literature on the subject in the hope of increasing awareness of the potential danger that may result from drug interactions." | ( Farah, RE; Makhoul, NM; Shai, MD, 2004) |
| "For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A)." | ( Agnelli, G; Büller, HR; Hull, RD; Hyers, TM; Prins, MH; Raskob, GE, 2004) |
| "First, can a subgroup of normotensive pulmonary embolism patients with a high risk for adverse outcomes, such as in-hospital mortality or early recurrent venous thromboembolism, be identified? Second, is there convincing evidence that the benefits of more aggressive therapy counterbalance its risks?Troponin I and T as well as brain natriuretic peptide (BNP) have recently been introduced as promising tools in the risk assessment of patients with pulmonary embolism." | ( Büller, HR; Söhne, M; Ten Wolde, M, 2004) |
| "To prevent pulmonary thromboembolism, prophylactic treatments were performed in 5 patients with DVT complications." | ( Aoki, H; Hiramatsu, N; Nomura, M; Takatori, M, 2005) |
| "Deep vein thrombosis (DVT) and pulmonary embolism (PE) are two manifestations of the same disorder, venous thromboembolism, and low-molecular weight heparin is the treatment of choice for both DVT and PE." | ( Eichinger, S, 2005) |
| "Massive pulmonary embolism is a potentially treatable catastrophic event after cesarean delivery, even if continuous cardiopulmonary resuscitation is required until life-saving embolectomy is done." | ( Greyson, B; Hilton, FL; Marty, AT; Spear, RK, 2005) |
| "In a mouse model of pulmonary thromboembolism induced by intravenous injection of type III collagen and epinephrine, prior administration of 80 mg/kg KOGEOGPK reduced by 50% the size of thrombi embolized in lungs, compared to vehicle-treated mice (p<0." | ( Amant, C; Bonnefoy, A; Da Nascimento, S; Fauvel-Lafeve, F; Kauskot, A; Legrand, C; Maurice, P; Pires, V; Rochette, J; Sonnet, P, 2006) |
| "Patients with deep venous thrombosis or pulmonary embolism received warfarin therapy; those with negative venograms received no further anticoagulation." | ( Donaldson, CT; Evarts, CM; Farber, DC; Lehman, EB; Pellegrini, VD, 2005) |
| "In the treatment of pulmonary embolism (PE), the presence of residual emboli is known to seriously affect the recurrence and prognosis." | ( Hiromoto, K; Naruse, H; Ohnishi, M; Ohyanagi, M; Takahashi, K; Ueda, A, 2005) |
| "We report a case of severe recurrent pulmonary embolism in which sildenafil was used as a rescue therapy." | ( Feihl, F; Ganière, V; Tagan, D, 2006) |
| "In this case, we describe pulmonary thromboembolism caused by hypercoagulable state associated with cholangiocarcinoma and speculate that such a thrombotic phenomenon could be regressed by anticoagulant therapy." | ( Bae, SH; Byun, JY; Choi, JY; Jang, JW; Jung, ES; Kim, JD; Rha, SE; Yeo, CD; Yoon, SK, 2006) |
| "Severe glue pulmonary embolism is a rare complication of injection therapy." | ( Alexander, S; Korman, MG; Sievert, W, 2006) |
| "Death from deep vein thrombosis or pulmonary embolism; failure to resolve, extension, recurrence of during treatment; recurrence after treatment; and major haemorrhage during treatment." | ( Bentley, DP; Campbell, IA; Prescott, RJ; Routledge, PA; Shetty, HG; Williamson, IJ, 2007) |
| "During treatment deep vein thrombosis or pulmonary embolism failed to resolve, extended, or recurred in six patients in the three month group without fatal consequences, compared with 10 in the six month group." | ( Bentley, DP; Campbell, IA; Prescott, RJ; Routledge, PA; Shetty, HG; Williamson, IJ, 2007) |
| "For example, deep-vein thrombosis and pulmonary embolism were statistically significantly higher in the tamoxifen arm than in the placebo arm during active treatment (52 versus 23 cases, RR = 2." | ( Cawthorn, S; Cuzick, J; Forbes, JF; Hamed, H; Holli, K; Howell, A; Sestak, I, 2007) |
| "Massive pulmonary embolism is a life-threatening condition to be treated with anticoagulants or even thrombolytic agents in selected cases." | ( Gualeni, A; Oneglia, C, 2008) |
| "Absence of pulmonary thromboembolism was defined as any patient still alive at least 3 months after the scan, with no anticoagulation treatment and no proof of pulmonary thromboembolism by other techniques, either at the time of the scan or during follow-up, or death by other causes." | ( Leblanc, M; Leveillée, F; Turcotte, E, 2007) |
| "We describe a unique case with ESRD and pulmonary embolism who was treated with fondaparinux owing to the toxicity and poor compliance with low-molecular-weight heparin." | ( Crandall, C; Lin, JJ; Pipe, S; Sharathkumar, AA, 2007) |
| "However, in patients with pulmonary embolism, idraparinux was less efficacious than standard therapy." | ( Buller, HR; Cohen, AT; Davidson, B; Decousus, H; Gallus, AS; Gent, M; Pillion, G; Piovella, F; Prins, MH; Raskob, GE, 2007) |
| "The current therapy of acute pulmonary embolism is focused on removing the mechanical obstruction of the pulmonary vessels." | ( Antunes, E; Cau, SB; de Nucci, G; Dias-Junior, CA; Montenegro, MF; Tanus-Santos, JE, 2008) |
| "Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen." | ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "The results of pulmonary embolism treatment with streptase in 76 patients are discussed." | ( Abramov, AS; Beskaeva, LM; Fineshin, IN; Gruzdev, AK; Malinovskiĭ, NN; Nikerov, KIu; Sal' nikov, DV, 2008) |
| "Elderly patients with idiopathic pulmonary embolism (PE) are at high risk for recurrent venous thromboembolic disease and might benefit from long-term anticoagulant therapy." | ( Bauer, K; Goehler, A; Haspel, J; Roberts, DH, 2009) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| "A 40-year-old woman admitted for massive pulmonary thromboembolism underwent anticoagulant and fibrinolytic therapy, following which warfarin was needed in unusually high doses to achieve effective anticoagulation." | ( Correia, MJ; Cortez-Dias, N; Coutinho, A; Diogo, AN; Fernandes, C; Lopes, MG, 2009) |
| "In patients with acute pulmonary embolism and right ventricular overload, treatment with epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload." | ( Boonstra, AB; Ijzerman, RG; Kamp, O; Kooter, AJ; Smulders, YM, 2010) |
| "In patients with acute pulmonary embolism and right ventricular overload, treatment with epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload." | ( Boonstra, AB; Ijzerman, RG; Kamp, O; Kooter, AJ; Smulders, YM, 2010) |
| "The morbidity and mortality of pulmonary embolism (PE) have been found to be related to early diagnosis and appropriate treatment." | ( Coelho, OR; Cortellazzi, L; Falcão, AL; Martins, LC; Moreira, MM; Moreno, H; Terzi, RG, 2010) |
| "Patients diagnosed with pulmonary embolism should be considered for treatment on an outpatient basis; however, this practise is not accepted in many centers." | ( Hawel, JD; Kovacs, MJ; Lazo-Langner, A; Rekman, JF, 2010) |
| "Symptomatic acute pulmonary embolism treatment with full therapeutic doses of tinzaparin for 6 months is a feasible alternative to conventional treatment with vitamin K antagonists." | ( Colomé-Nafria, E; Golpe, R; Leiro-Fernández, V; Méndez-Marote, L; Núñez-Delgado, JM; Palacios-Bartolomé, A; Pérez-de-Llano, LA, 2010) |
| "In patients with high-risk pulmonary embolism, NT-proBNP plasma levels experience rapid and significant reduction after successful invasive treatment." | ( Andresen, M; Castro, R; Córdova, S; Díaz, O; Fava, M; González, A; Meneses, L; Mercado, M, 2012) |
| "Traditionally, patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH)." | ( Creemers-Schild, D; de Vreede, MJ; Dekkers, OM; Dolsma, J; Eijsvogel, M; Faber, LM; Hofstee, HM; Hoogerbrugge, AD; Hovens, MM; Huisman, MV; Jonkers, GJ; Kruip, MJ; Mos, IC; van Kralingen, KW; Vlasveld, T; Zondag, W, 2011) |
| "Deep vein thrombosis and pulmonary embolism are not uncommon after major reconstructive surgery about the shoulder in untreated patients." | ( Abboud, JA; Bassora, R; Warrender, WJ; Widmer, BJ, 2011) |
| "In the setting of moderate impervious pulmonary embolism, treatment with a guanylate cyclase stimulator normalized pulmonary hemodynamics, reduced hemolysis, and improved oxygenation." | ( Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2011) |
| "Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal." | ( Büller, HR; Gallus, AS; Pillion, G; Prins, MH; Raskob, GE, 2012) |
| "Lastly, if pulmonary embolism occurred in association with cancer, anticoagulation should be conducted for 6 months or more if the cancer is active or treatment is on going." | ( Couturaud, F, 2011) |
| "For acute DVT or pulmonary embolism (PE), we recommend initial parenteral anticoagulant therapy (Grade 1B) or anticoagulation with rivaroxaban." | ( Akl, EA; Bounameaux, H; Comerota, AJ; Crowther, M; Dentali, F; Goldhaber, SZ; Gould, MK; Kahn, SR; Kearon, C; Nelson, ME; Prandoni, P; Wells, PS, 2012) |
| "Acute pulmonary thromboembolism was induced, after argan oil treatment, by an intravenous injection of a collagen and epinephrine mixture." | ( Aziz, M; Belmekki, F; Bnouham, M; Legssyer, A; Mekhfi, H; Ziyyat, A, 2012) |
| "Patients with pulmonary embolism should undergo risk stratification to establish whether they will benefit from the addition of advanced treatment, such as thrombolysis or embolectomy." | ( Bounameaux, H; Goldhaber, SZ, 2012) |
| "Thus, pulmonary thromboembolism is an inevitable consequence of successful adulticide therapy." | ( Carretón, E; González-Miguel, J; Juste, MC; Montoya-Alonso, JA; Morchón, R; Simón, F, 2013) |
| "Because we suspected septic pulmonary embolism related to the venous port, we removed the venous port promptly and administered antibiotics with a broad spectrum." | ( Daga, H; Miyamoto, N; Nishijima, M; Okada, H; Sumitani, M; Syoji, S; Taira, K; Takeda, K; Tokunaga, S; Tsuda, M, 2013) |
| "She subsequently experienced septic pulmonary embolism (SPE) and sacroiliitis during treatment with intravenous vancomycin and was successfully treated with long-term oral linezolid therapy." | ( Horai, Y; Ichinose, K; Iwamoto, N; Izumikawa, K; Kawakami, A; Kawashiri, SY; Kohno, S; Nakajima, H; Nakamura, H; Nakashima, Y; Oka, S; Origuchi, T; Suzuki, T; Tamai, M, 2014) |
| "We herein report a rare case of septic pulmonary embolism (SPE) caused by local infection-associated catheter removal during the administration of ABVd combination chemotherapy consisting of adriamycin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma of the mixed cellularity type." | ( Fukushima, T; Hyakuna, N; Masuzaki, H; Morichika, K; Nakachi, S; Nishi, Y; Shimabukuro, N; Tamaki, K; Tedokon, I; Tomoyose, T, 2014) |
| "Most patients with acute pulmonary embolism (PE) are still treated as inpatients." | ( Bajc, M; Elf, JE; Jögi, J, 2015) |
| "The revascularization therapy of pulmonary embolism is associated with ischemia-reperfusion (IR) injury." | ( Feng, C; Jin, Y; Li, H; Wang, Z; Zhang, W; Zhao, X, 2014) |
| "Septic pulmonary embolism (SPE) is an uncommon and severe infectious disease that requires early diagnosis and proper antibiotic therapy." | ( Fukuda, T; Inokuchi, R; Nakamura, K; Ohshima, K; Tokunaga, K; Yamamoto, M; Yasuda, M, 2015) |
| "Both were diagnosised as acute pulmonary embolism and recovered well after giving anticoagulant therapy in time." | ( Mu, L; Wang, R; Zhang, Y, 2015) |
| "Most of the patients with pulmonary embolism have in Finland been treated in inpatient wards, there is much to be learned about the identification of patients with low risk of death." | ( Harjola, VP, 2015) |
| "The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs)." | ( Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P, 2015) |
| "The standard treatment for pulmonary embolism is anticoagulant therapy using low molecular weight heparin, fondaparinux and a vitamin K antagonist, but a recent clinical trial showed that rivaroxaban, an oral factor Xa inhibitor, was as effective as standard therapy for the initial and long-term treatment of pulmonary embolism and had less bleeding complications." | ( Menegatti, E; Menichetti, M; Pazzaglia, M; Rosso, S, 2015) |
| "Previously, a pulmonary embolism was treated with the anticoagulants heparin and vitamin K antagonists." | ( Kesteven, P; McCaslin, JE; Robertson, L, 2015) |
| "The Home Treatment of Pulmonary Embolism (HoT-PE) study is a prospective international multicentre single-arm phase 4 management (cohort) trial aiming to determine whether home treatment of acute low-risk PE with the oral factor Xa inhibitor rivaroxaban is feasible, effective, and safe." | ( Barco, S; Bauersachs, R; Becattini, C; Beyer-Westendorf, J; Binder, H; Christ, M; Duerschmied, D; Empen, K; Fonseca, C; Held, M; Jiménez, D; Konstantinides, S; Lankeit, M; Quitzau, K; Schellong, S; Schwaiblmair, M, 2016) |
| "Outpatient treatment of pulmonary embolism (PE) may lead to improved patient satisfaction and reduced healthcare costs." | ( Brouwer, RE; de Vreede, MJ; den Exter, PL; Dolsma, J; Eijsvogel, M; Faber, LM; Grootenboers, MJ; Heller-Baan, R; Hovens, MM; Huisman, MV; Jonkers, GJ; Klok, FA; Melissant, CF; Peltenburg, H; Post, JP; van de Ree, MA; van Gerwen, M; van Kralingen, KW; Vlasveld, LT; Zondag, W, 2016) |
| "Traditionally, patients with pulmonary embolism (PE) are admitted from the emergency department and treated with low-molecular-weight heparin followed by warfarin." | ( Kabrhel, C; Merli, GJ; Peacock, WF; Pollack, C; Singer, AJ; Tapson, VF; Wildgoose, P; Xiang, J, 2016) |
| "After a pulmonary embolism, she was placed on anticoagulant therapy and on hospital discharge she was prescribed a vitamin K free diet to avoid interactions." | ( Cena, H; Fietchner, L; Fonte, ML; Manuelli, M, 2016) |
| "The severity of pulmonary embolism (PE) after isolated calf deep vein thrombosis (C-DVT) is controversial, which leads to inconsistent clinical decision making when treating C-DVT." | ( Garry, J; Labropoulos, N; Wu, AR, 2017) |
| "Choriocarcinoma accompanied with pulmonary embolism (PE) is rare and difficult to diagnose and treat." | ( Peng, L; Yang, M, 2017) |
| "A 71-year-old female with a history of pulmonary embolism treated with rivaroxaban presented with acute onset shortness of breath, chest pain and palpitations." | ( Bonanos, E; Burden, T; Medford, AR; Thompson, C, 2018) |
| "Massive pulmonary embolism with associated right heart failure is life-threatening, requiring treatment with anticoagulants or even thrombolytic agents." | ( Fang, HY; Lee, WC, 2018) |
| "Symptomatic bilateral pulmonary embolism may have a good prognosis if it is diagnosed early and treated appropriately." | ( Bourget-Murray, J; Clarke, MA; Gorzitza, S; Phillips, LA, 2018) |
| "We describe the case of pulmonary embolism in a DM1 patient, in which pulmonary thrombus was completely resolved with oral dabigatran etexilate therapy." | ( Cassese, A; Cimmino, G; Cioppa, ND; Gallinoro, E; Golino, P; Magliocca, MCG; Papa, AA; Rago, A; Sperlongano, S, 2018) |
| "We describe a case of suspected pulmonary embolism, followed by sudden death, in an elderly woman treated with oxygen-ozone therapy for lumbar pain caused by disk protrusion." | ( Chirchiglia, D; Chirchiglia, P; Lavano, A; Stroscio, C; Volpentesta, G, 2019) |
| "Unfortunately, pulmonary thromboembolism occurred 2 weeks later, and the patient's condition was not alleviated through active treatment." | ( Lan, HX; Lei, YY; Lu, MD; Ma, L; Wang, W; Xie, XY; Zhang, JC; Zhao, HJ, 2019) |
| "In patients with a first unprovoked pulmonary embolism, the HERDOO2 score is able to identify patients with a low recurrence risk after treatment discontinuation." | ( Bertoletti, L; Couturaud, F; Girard, P; Guégan, M; Hoffmann, C; Jego, P; Lacut, K; Laporte, S; Le Mao, R; Le Roux, PY; Lemarié, CA; Leroyer, C; Leven, F; Mélac, S; Meyer, G; Mismetti, P; Nonent, M; Pernod, G; Planquette, B; Presles, E; Raj, L; Robin, P; Sanchez, O; Slaun, PY; Tromeur, C, 2020) |
| "Here we report development of a pulmonary embolism (PE) in a young patient without other VTE risk factors who was treated for COVID-19 in an emergency department (ED) and discharged home without VTE prophylaxis, which was consistent with current recommendations." | ( Shapiro, NL; Uppuluri, EM, 2020) |
| "High-risk pulmonary embolism (PE) is a life-threatening condition that must be recognised and treated rapidly." | ( Fryk, K; Rylander, C; Svennerholm, K, 2020) |
| "The incidence of pulmonary embolism, deep venous thrombosis, major bleeding (MB), clinically relevant non-MB, acute respiratory distress syndrome, and in-hospital mortality was compared between patients on fondaparinux versus enoxaparin therapy." | ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "The CTPA revealed left pulmonary thromboembolism (PTE), treated with low-molecular-weight heparin." | ( Devi, S; Kar, N; Mohakud, S; Muthuvel, D, 2021) |
| "In response to pulmonary embolism after acetylcholine infusion against the background of pirenzepine pretreatment, the capillary hydrostatic pressure and postcapillary resistance did not change, while after atropine treatment, these parameters increased." | ( Berezina, TP; Evlakhov, VI; Ovsyannikov, VI; Poyassov, IZ, 2021) |
| "Patients with acute pulmonary embolism (PE) at low risk for short-term death are candidates for home treatment or short-hospital stay." | ( Agnelli, G; Becattini, C; Côté, B; den Exter, PL; Doukky, R; Erol, S; Jiménez, D; Khemasuwan, D; Maraziti, G; Ng, ACC; Ozsu, S; Polo Friz, H; Soares, TH; Vanni, S; Vinson, DR; Weekes, AJ, 2021) |
| "The observed decreasing trends in pulmonary embolism-related mortality might reflect improved management of the disease including new treatment options as well as advances in imaging technologies." | ( Barco, S; Hobohm, L; Johner, F; Keller, K; Konstantinides, SV; Kucher, N; Mahmoudpour, SH; Münzel, T; Sebastian, T; Valerio, L; Vatsakis, G, 2022) |
| "After the treatment of pulmonary thromboembolism and venous thrombosis with rivaroxaban, surgical thrombectomy of the left popliteal artery, patent foramen ovale closure, and total hysterectomy were performed." | ( Kim, JH; Koo, J; Lee, K, 2022) |
| "The very early management of pulmonary embolism (PE), a part from antithrombotic treatment, has been little studied." | ( Asarisi, F; Berkane, N; Breittmayer, JP; Bun, S; Doyen, D; Ferrari, E; Fourrier, E; Heme, N; Labbaoui, M; Moceri, P; Redjimi, N; Sartre, B; Squara, F, 2022) |
| "We present a case of pulmonary embolism (PE) and bradycardia in a 91-year-old NSCLC patient treated with crizotinib for a rare MET Y1003S mutation." | ( Chen, Y; Ding, Y; Jin, W; Qiu, Z; Shi, Y; Zhang, A, 2023) |
| "Patients without pulmonary embolism (PE) were mostly omitted from initial unfractionated heparin (UFH) therapy prior to administration of edoxaban." | ( Kato, S; Odajima, S; Okamoto, A; Saito, M; Seki, T; Shoburu, Y; Suzuki, E; Takano, H; Takenaka, M; Tomita, K; Yamada, K, 2022) |
| "Chronic pulmonary thromboembolism (CTEPH) is an unusual complication of acute pulmonary embolism (PE), which is now considered to be treatable." | ( Abbasi, B; Akhavan, R; Darvish, A; Dehghani, S; Emadzadeh, M; Farrokh, D; Pezeshki Rad, M, 2022) |
| "Thrombosis can cause graft loss and pulmonary embolism, thus appropriate administration of activated protein C concentrate may help prevent thrombosis." | ( Ashizawa, T; China, T; Horie, S; Ikehata, Y; Ishikawa, K; Isotani, S; Kawano, H; Maiguma, M; Muto, S; Nagashima, Y; Nagata, M; Nagaya, N; Nakagawa, Y; Nakamura, S; Shimizu, F; Shirakawa, T; Suzuki, Y; Yoshiyama, A; Yuzawa, K, 2022) |
| "Thrombosis can cause graft loss and pulmonary embolism, thus appropriate administration of activated protein C concentrate may help prevent thrombosis." | ( Ashizawa, T; China, T; Horie, S; Ikehata, Y; Ishikawa, K; Isotani, S; Kawano, H; Maiguma, M; Muto, S; Nagashima, Y; Nagata, M; Nagaya, N; Nakagawa, Y; Nakamura, S; Shimizu, F; Shirakawa, T; Suzuki, Y; Yoshiyama, A; Yuzawa, K, 2022) |
| "Thrombosis can cause graft loss and pulmonary embolism, thus appropriate administration of activated protein C concentrate may help prevent thrombosis." | ( Ashizawa, T; China, T; Horie, S; Ikehata, Y; Ishikawa, K; Isotani, S; Kawano, H; Maiguma, M; Muto, S; Nagashima, Y; Nagata, M; Nagaya, N; Nakagawa, Y; Nakamura, S; Shimizu, F; Shirakawa, T; Suzuki, Y; Yoshiyama, A; Yuzawa, K, 2022) |
| "In patients with intermediate-risk pulmonary embolism (PE), reversal of hypoxic vasoconstriction could constitute a target for treatment that protects the right ventricular (RV) function until endogenous fibrinolysis occurs." | ( Barrios, D; Bikdeli, B; Chasco, L; Durán, D; Jara-Palomares, L; Jiménez, D; Lobo, JL; López-Reyes, R; Moisés, J; Monreal, M; Retegui, A; Rodríguez, C, 2023) |
| "In patients with intermediate-risk pulmonary embolism (PE), reversal of hypoxic vasoconstriction could constitute a target for treatment that protects the right ventricular (RV) function until endogenous fibrinolysis occurs." | ( Barrios, D; Bikdeli, B; Chasco, L; Durán, D; Jara-Palomares, L; Jiménez, D; Lobo, JL; López-Reyes, R; Moisés, J; Monreal, M; Retegui, A; Rodríguez, C, 2023) |
| "In patients with intermediate-risk pulmonary embolism (PE), reversal of hypoxic vasoconstriction could constitute a target for treatment that protects the right ventricular (RV) function until endogenous fibrinolysis occurs." | ( Barrios, D; Bikdeli, B; Chasco, L; Durán, D; Jara-Palomares, L; Jiménez, D; Lobo, JL; López-Reyes, R; Moisés, J; Monreal, M; Retegui, A; Rodríguez, C, 2023) |